# OnCo record idea-nl-glp1-adjuvant-hr-breast (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-nl-glp1-adjuvant-hr-breast/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-nl-glp1-adjuvant-hr-breast" ;
  schema:name "GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer"@en ;
  schema:description "Coaching-based weight loss did not clearly cut breast cancer recurrence in BWEL, perhaps because the weight loss was too small. Drugs that produce three times as much weight loss could settle whether weight itself matters."@en ;
  schema:url <https://onco.cc/ideas/idea-nl-glp1-adjuvant-hr-breast/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://cancercontrol.cancer.gov/ocs/statistics> ;
  onco:related <https://onco.cc/ideas/idea-prev-glp1-cancer-prevention-rct/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:sections <https://onco.cc/fronts/nutrition-lifestyle/>, <https://onco.cc/fronts/hormonal/> ;
  onco:technologies <https://onco.cc/technologies/glp1-agonists-cancer-risk/>, <https://onco.cc/technologies/dietitian-led-weight-loss-breast/>, <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/resistance-training-cachexia/> ;
  onco:drugs <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/abemaciclib/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:terms <https://onco.cc/terms/obesity-related-cancers/>, <https://onco.cc/terms/energy-balance/>, <https://onco.cc/terms/body-composition/> ;
  onco:trials <https://onco.cc/trials/bwel/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-funding-allocation/> .